

ORIGINAL

Attorney Docket No. Le A 34 750D1

PATENT

In re application of: Bischoff, et al.

Application No.: 10/715,283

Group No.: 1624

Filed: 11/17/2003


Examiner: Patel, S.

For: Substituted Phenylcyclohexanecarboxamides and their Use

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 21 Sept. 04


William F. Gray

**MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. Box 1450
ALEXANDRIA, VA 22202**

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING DATE OF EITHER A FINAL ACTION
OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))**

**TIME OF TRANSMITTAL OF ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

1. The information disclosure statement transmitted herewith is being filed **after** three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but **before** the mailing date of either

- (1) a final action under section 1.113 or
- (2) a notice of allowance under section 1.311 or
- (3) any other action closing prosecution

whichever occurs first.

Attorney Docket No. Le A 34 750D1

09/24/2004 DEMMANU1 00000005 133372 10715283

1

02 FC:1806 180.00 DA

FEE

2. Applicant elects the option to pay the fee set forth in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under § 1.97(c) (\$180.00).

Fee due \$ 180.00

METHOD OF PAYMENT OF FEE


3. Please charge Account No. 13-3372 in the amount of \$ 180.00. The Commissioner is also authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Reg. No. 31,018

Telephone: (203) 812-2712

Date: September 21, 2004



William F. Gray
Attorney for Applicant(s)
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516

Form PTO-1449 (Modified) <div style="position: absolute; top: 0; left: 50px; border: 1px solid black; border-radius: 50%; padding: 5px; text-align: center;"> O I P E SEP 23 2004 JCTO </div>	U.S. Department of Commerce Patent and Trademark Office		Serial No. 10/715,283	Group Art Unit 1624	Filing Date 11/17/2003	Atty. Docket No. Le A 34750D1
	INFORMATION DISCLOSURE CITATION		Applicant(s) Bischoff, et al.			

U.S. PATENT DOCUMENTS

*		DOCUMENT NO.	DATE MM/DD/YY	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	F1	0 5 8 2 1 6 4	09/02/94	EP				
	F2	0 6 1 1 7 6 7	24/08/94	EP				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

R1	Becker, L.C., "Conditions for Vasodilator-induced Coronary Steal in Experimental Myocardial Ischemia", Circulation, <u>57</u> (6): 1103-1110 (1978).
R2	DeNinno, M.P., "Annual Reports in Medicinal Chemistry", <u>33</u> : 111-120 (1998).
R3	Makarewicz, W., "Response of Purine Metabolism to Hypoxia and Ischemia, Purine and Pyrimidine Metabolism in Man", Plenum Press, New York, <u>11</u> : 351-357 (1998).
R4	Marangos, P.J et al., Potential Therapeutic Roles for Adenosine in Neurologic Disease, Adenosine in the Nervous System," Eds. Stone, T., Academic Press Ltd., p.p. 217-227 (1991).
R5	Murray, T.F. et al., "Manipulation of Endogenous Adenosine Affects Seizure Susceptibility", Drug Development Research, <u>28</u> , 410-415 (1993).
R6	Porkka-Heiskanen, T. et al., "Adenosine: A Mediator of the Sleep-Inducing Effects of Prolonged Wakefulness", Science, <u>276</u> : 1265-1268 (1997).
R7	Rudolphi, K. A. et al., "Adenosine and Brain Ischemia", Cerebrovascular and Brain Metabolism Review, <u>4</u> : 346-369 (1992).
R8	Strasser, R et al., Zeitschrift fur Kardologie, <u>85</u> (2): 79-89 (1996).
R9	Sear, J.W. et al., "Issues In the perioperative management of the elderly patient with cardiovascular disease", Pub Med Abstract 12149050; Drugs Aging <u>19</u> , 429-451 (2002).
R10	Sawynok J. et al., "Pharmacological rationale for the clinical use of caffeine, PubMed Abstract 7705215, Drugs, <u>49</u> , 37-50 (1995).

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

	R11	Jurkowitz, M.S. et al., "Adenosine, inosine, and guanosine protect glial cells during glucose deprivation and mitochondrial inhibition: correlation between Protection and ATP preservation," PubMed Abstract 9681443; J. Neurochem, <u>71</u> , 535-548 (1998).
--	------------	--

EXAMINER	DATE CONSIDERED
<p>* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	